Tarsus Pharmaceuticals annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Tarsus Pharmaceuticals Depreciation & Amortization Growth & History (TARS)
Tarsus Pharmaceuticals's depreciation and amortization was $1.8M for fiscal 2025.
View full Tarsus Pharmaceuticals company overviewTarsus Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.8M | $591,000 | +48.24% |
| 2024 | 2024-12-31 | $1.2M | $348,000 | +39.68% |
| 2023 | 2023-12-31 | $877,000 | $551,000 | +169.02% |
| 2022 | 2022-12-31 | $326,000 | $26,000 | +8.67% |
| 2021 | 2021-12-31 | $300,000 | $200,000 | +200.00% |
| 2020 | 2020-12-31 | $100,000 | $63,000 | +170.27% |
| 2019 | 2019-12-31 | $37,000 | — | — |
Tarsus Pharmaceuticals quarterly depreciation and amortization
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.0M | $600,000 | +150.00% |
| Q1 2026 | 2026-03-31 | $437,000 | −$23,000 | −5.00% |
| Q4 2025 | 2025-12-31 | $443,000 | — | — |
| Q3 2025 | 2025-09-30 | $400,000 | $100,000 | +33.33% |
| Q2 2025 | 2025-06-30 | $400,000 | $200,000 | +100.00% |
| Q1 2025 | 2025-03-31 | $460,000 | $190,000 | +70.37% |
| Q3 2024 | 2024-09-30 | $300,000 | $100,000 | +50.00% |
| Q2 2024 | 2024-06-30 | $200,000 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $270,000 | $166,000 | +159.62% |
| Q3 2023 | 2023-09-30 | $200,000 | $100,000 | +100.00% |
| Q2 2023 | 2023-06-30 | $200,000 | $100,000 | +100.00% |
| Q1 2023 | 2023-03-31 | $104,000 | $4,000 | +4.00% |
| Q3 2022 | 2022-09-30 | $100,000 | $0 | 0.00% |
| Q2 2022 | 2022-06-30 | $100,000 | −$25,000 | −20.00% |
| Q1 2022 | 2022-03-31 | $100,000 | $36,000 | +56.25% |
| Q3 2021 | 2021-09-30 | $100,000 | $76,000 | +316.67% |
| Q2 2021 | 2021-06-30 | $125,000 | $108,000 | +635.29% |
| Q1 2021 | 2021-03-31 | $64,000 | $49,000 | +326.67% |
| Q3 2020 | 2020-09-30 | $24,000 | $15,000 | +166.67% |
| Q2 2020 | 2020-06-30 | $17,000 | — | — |
| Q1 2020 | 2020-03-31 | $15,000 | — | — |
| Q3 2019 | 2019-09-30 | $9,000 | — | — |
Tarsus Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, Tarsus Pharmaceuticals's depreciation and amortization increased from $100,000 to $1.8M, a change of $1.7M. The latest reported quarter, Q2 2026, shows $1.0M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tarsus Pharmaceuticals source filings ↗